Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 4/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.50 |
| ▸ | MAPT | P10636 | 3/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.50 |
| ▸ | MYOC | Q99972 | 1/20 | 0.50 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.47 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.47 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | ACHE | P22303 | 3/20 | 0.37 |
| ▸ | BCHE | P06276 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18930369 | 0.86 | TRPA1 (0.43) | MEN1KMT2AMAPTNPSR1MYOC | |
| SCHEMBL20707093 | 0.84 | MEN1 (0.51) | MEN1KMT2AMAPTNPSR1MYOC | |
| SCHEMBL26080097 | 0.82 | ALDH1A1 (0.47) | MEN1KMT2AMAPTNPSR1ALDH1A1 | |
| SCHEMBL18932088 | 0.80 | MEN1 (0.47) | MEN1KMT2AMAPTNPSR1MYOC | |
| SCHEMBL21568091 | 0.79 | MEN1 (0.58) | MEN1KMT2AMAPTNPSR1MYOC | |
| SCHEMBL13170071 | 0.77 | MEN1 (0.57) | MEN1KMT2AMAPTNPSR1MYOC | |
| SCHEMBL20825702 | 0.76 | MEN1 (0.56) | MEN1KMT2AMAPTNPSR1MYOC | |
| SCHEMBL8295751 | 0.76 | MEN1 (0.51) | MEN1KMT2AMAPTNPSR1MYOC | |
| SCHEMBL25490648 | 0.76 | MEN1 (0.52) | MEN1KMT2AMAPTNPSR1MYOC | |
| SCHEMBL11636315 | 0.75 | LMNA (0.56) | MEN1KMT2AMAPTNPSR1MYOC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230285378-A1 | Anti-Viral Compounds | ABBVIE INC. (US) | 2023-09-14 | — | — | US | disclosed |
| US-20210238226-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | Design Therapeutics, Inc. | 2021-08-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210238226-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | ATXN2L, ATXN2, ATXN10 | MEN1 3416/4885KMT2A 2202/4885MAPT 446/4885 |
| US-20230285378-A1 | Anti-Viral Compounds | HAVCR2, EIF2AK2, MAVS | MEN1 4681/4885KMT2A 4093/4885MAPT 2833/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.